Compared with TNF inhibitors, tocilizumab monotherapy improves the healing of focal bone erosions in RA patients and outperforms methotrexate or other csDMARDs in terms of lowering RA symptoms (330). The gene discussed is TNF; the disease is rheumatoid arthritis.